Report Thumbnail
Product Code LP09153104733XF
Published Date 2023/2/28
English97 PagesGlobal

Global Biofermin Market Growth 2023-2029Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP09153104733XF◆The Feb 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/2/28
English 97 PagesGlobal

Global Biofermin Market Growth 2023-2029Pharmaceutical_LifeSciense Market



Abstract


Summary

Lactase is a drying agent of live enterococcus. It decomposes sugars into lactic acid in the intestine, which increases the acidity of the intestine, inhibits the growth and reproduction of putrefactive bacteria, prevents intestinal fermentation and reduces gas production, thus promoting digestion and stopping diarrhea.
LPI (LP Information)' newest research report, the “Biofermin Industry Forecast” looks at past sales and reviews total world Biofermin sales in 2022, providing a comprehensive analysis by region and market sector of projected Biofermin sales for 2023 through 2029. With Biofermin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biofermin industry.
This Insight Report provides a comprehensive analysis of the global Biofermin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biofermin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Biofermin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biofermin and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biofermin.
The global Biofermin market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Biofermin is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Biofermin is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Biofermin is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Biofermin players cover Guilin Pharmaceutical, Sinoway Pharmaceutical, Hebei Huanhai Pharmaceutical, Hebei Tianyuan Pharmaceutical, Shandong Baiwei Pharmaceutical, Huibei Widely Chemical Technology, Okobaike Biotechnology and Taisho, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Biofermin market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Tablets
Powdery
Other
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Guilin Pharmaceutical
Sinoway Pharmaceutical
Hebei Huanhai Pharmaceutical
Hebei Tianyuan Pharmaceutical
Shandong Baiwei Pharmaceutical
Huibei Widely Chemical Technology
Okobaike Biotechnology
Taisho
Key Questions Addressed in this Report
What is the 10-year outlook for the global Biofermin market?
What factors are driving Biofermin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biofermin market opportunities vary by end market size?
How does Biofermin break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Biofermin Annual Sales 2018-2029
      • 2.1.2 World Current & Future Analysis for Biofermin by Geographic Region, 2018, 2022 & 2029
      • 2.1.3 World Current & Future Analysis for Biofermin by Country/Region, 2018, 2022 & 2029
    • 2.2 Biofermin Segment by Type
      • 2.2.1 Tablets
      • 2.2.2 Powdery
      • 2.2.3 Other
    • 2.3 Biofermin Sales by Type
      • 2.3.1 Global Biofermin Sales Market Share by Type (2018-2023)
      • 2.3.2 Global Biofermin Revenue and Market Share by Type (2018-2023)
      • 2.3.3 Global Biofermin Sale Price by Type (2018-2023)
    • 2.4 Biofermin Segment by Application
      • 2.4.1 Hospital Pharmacies
      • 2.4.2 Retail Pharmacies
      • 2.4.3 Online Pharmacies
    • 2.5 Biofermin Sales by Application
      • 2.5.1 Global Biofermin Sale Market Share by Application (2018-2023)
      • 2.5.2 Global Biofermin Revenue and Market Share by Application (2018-2023)
      • 2.5.3 Global Biofermin Sale Price by Application (2018-2023)
  • 3 Global Biofermin by Company

    • 3.1 Global Biofermin Breakdown Data by Company
      • 3.1.1 Global Biofermin Annual Sales by Company (2018-2023)
      • 3.1.2 Global Biofermin Sales Market Share by Company (2018-2023)
    • 3.2 Global Biofermin Annual Revenue by Company (2018-2023)
      • 3.2.1 Global Biofermin Revenue by Company (2018-2023)
      • 3.2.2 Global Biofermin Revenue Market Share by Company (2018-2023)
    • 3.3 Global Biofermin Sale Price by Company
    • 3.4 Key Manufacturers Biofermin Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Biofermin Product Location Distribution
      • 3.4.2 Players Biofermin Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Biofermin by Geographic Region

    • 4.1 World Historic Biofermin Market Size by Geographic Region (2018-2023)
      • 4.1.1 Global Biofermin Annual Sales by Geographic Region (2018-2023)
      • 4.1.2 Global Biofermin Annual Revenue by Geographic Region (2018-2023)
    • 4.2 World Historic Biofermin Market Size by Country/Region (2018-2023)
      • 4.2.1 Global Biofermin Annual Sales by Country/Region (2018-2023)
      • 4.2.2 Global Biofermin Annual Revenue by Country/Region (2018-2023)
    • 4.3 Americas Biofermin Sales Growth
    • 4.4 APAC Biofermin Sales Growth
    • 4.5 Europe Biofermin Sales Growth
    • 4.6 Middle East & Africa Biofermin Sales Growth
  • 5 Americas

    • 5.1 Americas Biofermin Sales by Country
      • 5.1.1 Americas Biofermin Sales by Country (2018-2023)
      • 5.1.2 Americas Biofermin Revenue by Country (2018-2023)
    • 5.2 Americas Biofermin Sales by Type
    • 5.3 Americas Biofermin Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Biofermin Sales by Region
      • 6.1.1 APAC Biofermin Sales by Region (2018-2023)
      • 6.1.2 APAC Biofermin Revenue by Region (2018-2023)
    • 6.2 APAC Biofermin Sales by Type
    • 6.3 APAC Biofermin Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan
  • 7 Europe

    • 7.1 Europe Biofermin by Country
      • 7.1.1 Europe Biofermin Sales by Country (2018-2023)
      • 7.1.2 Europe Biofermin Revenue by Country (2018-2023)
    • 7.2 Europe Biofermin Sales by Type
    • 7.3 Europe Biofermin Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Biofermin by Country
      • 8.1.1 Middle East & Africa Biofermin Sales by Country (2018-2023)
      • 8.1.2 Middle East & Africa Biofermin Revenue by Country (2018-2023)
    • 8.2 Middle East & Africa Biofermin Sales by Type
    • 8.3 Middle East & Africa Biofermin Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Biofermin
    • 10.3 Manufacturing Process Analysis of Biofermin
    • 10.4 Industry Chain Structure of Biofermin
  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Biofermin Distributors
    • 11.3 Biofermin Customer
  • 12 World Forecast Review for Biofermin by Geographic Region

    • 12.1 Global Biofermin Market Size Forecast by Region
      • 12.1.1 Global Biofermin Forecast by Region (2024-2029)
      • 12.1.2 Global Biofermin Annual Revenue Forecast by Region (2024-2029)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Biofermin Forecast by Type
    • 12.7 Global Biofermin Forecast by Application
  • 13 Key Players Analysis

    • 13.1 Guilin Pharmaceutical
      • 13.1.1 Guilin Pharmaceutical Company Information
      • 13.1.2 Guilin Pharmaceutical Biofermin Product Portfolios and Specifications
      • 13.1.3 Guilin Pharmaceutical Biofermin Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.1.4 Guilin Pharmaceutical Main Business Overview
      • 13.1.5 Guilin Pharmaceutical Latest Developments
    • 13.2 Sinoway Pharmaceutical
      • 13.2.1 Sinoway Pharmaceutical Company Information
      • 13.2.2 Sinoway Pharmaceutical Biofermin Product Portfolios and Specifications
      • 13.2.3 Sinoway Pharmaceutical Biofermin Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.2.4 Sinoway Pharmaceutical Main Business Overview
      • 13.2.5 Sinoway Pharmaceutical Latest Developments
    • 13.3 Hebei Huanhai Pharmaceutical
      • 13.3.1 Hebei Huanhai Pharmaceutical Company Information
      • 13.3.2 Hebei Huanhai Pharmaceutical Biofermin Product Portfolios and Specifications
      • 13.3.3 Hebei Huanhai Pharmaceutical Biofermin Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.3.4 Hebei Huanhai Pharmaceutical Main Business Overview
      • 13.3.5 Hebei Huanhai Pharmaceutical Latest Developments
    • 13.4 Hebei Tianyuan Pharmaceutical
      • 13.4.1 Hebei Tianyuan Pharmaceutical Company Information
      • 13.4.2 Hebei Tianyuan Pharmaceutical Biofermin Product Portfolios and Specifications
      • 13.4.3 Hebei Tianyuan Pharmaceutical Biofermin Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.4.4 Hebei Tianyuan Pharmaceutical Main Business Overview
      • 13.4.5 Hebei Tianyuan Pharmaceutical Latest Developments
    • 13.5 Shandong Baiwei Pharmaceutical
      • 13.5.1 Shandong Baiwei Pharmaceutical Company Information
      • 13.5.2 Shandong Baiwei Pharmaceutical Biofermin Product Portfolios and Specifications
      • 13.5.3 Shandong Baiwei Pharmaceutical Biofermin Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.5.4 Shandong Baiwei Pharmaceutical Main Business Overview
      • 13.5.5 Shandong Baiwei Pharmaceutical Latest Developments
    • 13.6 Huibei Widely Chemical Technology
      • 13.6.1 Huibei Widely Chemical Technology Company Information
      • 13.6.2 Huibei Widely Chemical Technology Biofermin Product Portfolios and Specifications
      • 13.6.3 Huibei Widely Chemical Technology Biofermin Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.6.4 Huibei Widely Chemical Technology Main Business Overview
      • 13.6.5 Huibei Widely Chemical Technology Latest Developments
    • 13.7 Okobaike Biotechnology
      • 13.7.1 Okobaike Biotechnology Company Information
      • 13.7.2 Okobaike Biotechnology Biofermin Product Portfolios and Specifications
      • 13.7.3 Okobaike Biotechnology Biofermin Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.7.4 Okobaike Biotechnology Main Business Overview
      • 13.7.5 Okobaike Biotechnology Latest Developments
    • 13.8 Taisho
      • 13.8.1 Taisho Company Information
      • 13.8.2 Taisho Biofermin Product Portfolios and Specifications
      • 13.8.3 Taisho Biofermin Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.8.4 Taisho Main Business Overview
      • 13.8.5 Taisho Latest Developments
  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.